← boardnext 2026-12-31
CERO
CERo Therapeutics Holdings, Inc.distress 8/10 · high distress / dilution risk$0.01-8%today-100% from 52w high
Lead: Acute Myeloid Leukemia · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
+3642%
Price & events
-77.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-8.3%
1D
-8.3%
1W
+22.2%
1M
-65.6%
3M
-77.1%
6M
-99.9%
1Y
-100.0%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $496.24K
- Enterprise Value
- $-224.49K
- Volume
- 886.50K
- 52 Week Range
- $0.01 – $8.85
- Total Shares
- 45.11M
- Float Shares
- 43.33M
- Short %
- 10.50%
- % Held by Insiders
- 4.13%
- % Held by Institutions
- 0.14%
- RVOL
- 0.97x
- Beta
- 0.16
Pipeline stages · 1 programs
CER-1236, Cyclophosphamide, Fludarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | CER-1236, Cyclophosphamide, Fludarabinefast track | AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | — | recruiting |
Catalyst news & presentations · 3
- beginning on February 4, 2026conferencedata presentationsecondaryCER-1236 · Poster presentation at Transplantation and Cellular Therapy Meetings.SEC 8-K
- 2025-10-29withdrawalNasdaq Hearings Panel denied continued listing of common stock; suspension at open on October 31, 2025.SEC 8-K
- 2024-07-26clinical holdCER-1236 · FDA placed clinical hold on IND for CER-1236 due to insufficient pharmacology/toxicology dataSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 45,112,406 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-11-18D. Boral CapitalBuy → Hold
- 2025-10-30D. Boral CapitalBuy
- 2025-10-22D. Boral CapitalBuy
- 2025-10-13D. Boral CapitalBuy
- 2025-09-23D. Boral CapitalBuy
- 2025-09-09D. Boral CapitalBuy
Competitors — Acute Myeloid Leukemia
- ABBVAbbVie Inc.$451.1B · D2
- SLSSELLAS Life Sciences Group, Inc.$2.2B · D4
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- KURAKura Oncology, Inc.$917M · D5
- FHTXFoghorn Therapeutics Inc.$303M · D4
- DTILPRECISION BIOSCIENCES INC$185M · D6
- BMEABiomea Fusion, Inc.$90M · D6
- INABIN8BIO, INC.$12M · D7
- MBRXMoleculin Biotech, Inc.$11M · D8
- BPTHBIO-PATH HOLDINGS, INC.$2M · D9
Recent news
- 2026-07-17CERo Therapeutics Expands Convertible Debt Financing Arrangement - TipRanks
- 2026-07-17CERO Therapeutics (OTCQB: CERO) details $2,606,500 discounted convertible note funding - Stock Titan
- 2026-07-17Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027 - TradingView
- 2026-07-17CERO Therapeutics (CERO) details $2,085,200 10% convertible note deal - Stock Titan
- 2026-07-13CERo Therapeutics Holdings, Inc. announced that it has received $2.0852 million in funding from SRx Health Solutions Inc. - marketscreener.com
- 2026-07-13CERO Therapeutics (NASDAQ: CERO) set for share and warrant delisting - Stock Titan
- 2026-06-26CERO Therapeutics (OTCQB: CERO) registers 729.6M shares; files convertible note details - Stock Titan
- 2026-06-26CERO Therapeutics (CERO) inks $1.41M 10% convertible note with stock conversion - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.